-+ 0.00%
-+ 0.00%
-+ 0.00%

Acrivon Therapeutics announces availability of new press release

PUBT·07/21/2026 20:31:51
Listen to the news
Acrivon Therapeutics announces availability of new press release
  • Acrivon posted a press release outlining AACR D3 2026 oral and poster presentations highlighting its AP3 platform, centered on WEE1/PKMYT1 inhibitor ACR-2316.
  • ACR-2316 Phase 1/2 data cited early tumor shrinkage, including partial responses, across AP3-predicted tumor types not previously sensitive to WEE1-class agents.
  • Conference presentations scheduled July 22-23 in Boston; ACR-2316 is advancing toward dose expansion.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acrivon Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607211630PRIMZONEFULLFEED9765801) on July 21, 2026, and is solely responsible for the information contained therein.